Efficacy and safety of an early response‐based tapering regimen of tocilizumab in children with systemic juvenile idiopathic arthritis
International Journal of Rheumatic Diseases · 2024
DOI: 10.1111/1756-185x.15196 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Soumya Dey und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Antibodies, Monoclonal, Humanized, Drug Tapering, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Systemic juvenile idiopathic arthritis (sJIA) is a distinct disease subset, with a poorer prognosis compared with other JIA subsets. Tocilizumab has an important role in the management of sJIA refractory to standard initial therapy. However, no specific guidelines exist for the tapering of tocilizumab therapy in sJIA, which could have implications on the overall cost and side effects of treatment.
Methods
This was an observational study which included 21 children with refractory sJIA, who were initially put on injection tocilizumab every 2 weekly, with subsequent dosing tapered to 4 weekly and 6 weekly intervals based on JIA ACR 70 responses at 12 and 24 weeks, respectively. The primary outcome at week 36 included JIA ACR 30, 50, 70, and 90 response rates with other efficacy and safety measures as secondary outcomes.
Results
At 36 weeks, JIA ACR 30, 50, 70, and 90 responses were observed in 90.5%, 90.5%, 71.4%, and 52.4% patients respectively along with significant improvement in hematological and inflammatory parameters. The mean prednisolone dose could be reduced from 0.54 to 0.13 mg/kg/day and around 29% patients were able to discontinue steroids altogether. No serious adverse events were recorded. With drug tapering, we could curtail on 26% of the total tocilizumab dose that would have been otherwise required on the continuous 2 weekly protocol.
Conclusions
Tocilizumab, used in an early response‐based tapering regimen, was both safe and efficacious in children with sJIA refractory to standard therapy. Larger and longer duration studies are required to further validate our observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology and Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India.
ORCID-Profile: Debaditya Roy, Alakendu Ghosh
Zitieren
APA
Dey, S., Roy, D., Sinhamahapatra, P., & Ghosh, A. (2024). Efficacy and safety of an early response‐based tapering regimen of tocilizumab in children with systemic juvenile idiopathic arthritis. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15196
Vancouver
Dey S, Roy D, Sinhamahapatra P, Ghosh A. Efficacy and safety of an early response‐based tapering regimen of tocilizumab in children with systemic juvenile idiopathic arthritis. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15196
BibTeX
@article{Dey2024,
author = {Dey, Soumya and Roy, Debaditya and Sinhamahapatra, Pradyot and Ghosh, Alakendu},
title = {Efficacy and safety of an early response‐based tapering regimen of tocilizumab in children with systemic juvenile idiopathic arthritis},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
doi = {10.1111/1756-185x.15196}
}
EUVIMED